Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
ReproCELL
Yokohama, Japan
A
51-100 Employees
2003
Key takeaway
REPROCELL offers a comprehensive portfolio that includes induced pluripotent stem cells (iPSCs), which are critical for cell line development and translational research. Their expertise in stem cell research and 3D bioengineered tissues supports innovative therapies and clinical applications.
Reference
Product
Products: Cell Substrates
Browse a range of cell substrates on the REPROCELL website. Request a quote for delivery to the USA or Europe today.
ThinkCyte
Tokyo, Japan
A
11-50 Employees
2016
Key takeaway
The company focuses on advancing cell therapy through innovative techniques like Ghost Cytometry, which enables label-free characterization and isolation of cells at high throughput. This approach enhances the development of therapies by allowing precise identification of various cell types based on morphological differences, without the need for physical markers.
Reference
Product
Cell Therapy - ThinkCyte
Label-free Monitoring and Isolation of Target Cells Our Solution for Cell Therapy Conventionally, surface markers or stains have been necessary to characterize and isolate target cells in the cell therapy manufacturing process. By applying Ghost Cytometry, we perform label-free characterization and isolation of cells at high throughput by using machine predicted “in-silico” labels. Our technology can classify and isolate cells based on morphological differences and has been used for identifying live and dead cells, activated and resting T cells, and differentiated and undifferentiated stem cells. It has also been used to assess more subtle morphological variations in cells and organelles including cell-cycle phases, glycolytic levels, and apoptotic status. This technology … Continued
MiCAN Technologies
Kyoto, Japan
A
1-10 Employees
2016
Key takeaway
MiCAN Technologies, Inc. specializes in the development and provision of high precision artificial blood cells, including their innovative cMylc cells designed for evaluating the efficacy and safety of vaccines and drugs, particularly for COVID-19. Their use of iPS cell technology enables the production of uniform blood cells with identical genetic backgrounds, which can significantly enhance research efforts in drug development and infectious disease studies.
Reference
Core business
MiCAN Technologies / マイキャン・テクノロジーズ株式会社
For research on malaria,our newly developed MPV cells will solve the shortage of supply of reticulocyte cells and support researches to eradicate such diseases.
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
PhoenixBio
Higashi Hiroshima, Japan
A
51-100 Employees
2002
Key takeaway
The company specializes in enhancing drug discovery and development through innovative models and services, including the use of PXB-cells®, which are primary human hepatocytes derived from their humanized liver mouse model. This approach provides greater translational relevance for preclinical drug testing, offering valuable insights into human outcomes.
Reference
Product
PXB-cells
Boost the translational quality of preclinical drug development and discovery projects with PXB-cells
Molcure
Tokyo, Japan
A
11-50 Employees
2013
Key takeaway
The company leverages over 1 billion proprietary biopharmaceutical data points and advanced AI technology to enhance drug discovery. Their use of directed evolution experiments and machine learning models allows for the rapid identification and prediction of key properties of biopharmaceuticals.
Reference
Core business
Molcure Inc. | Accelerating drug discovery
Minaris Regenerative Medicine
Tokyo, Japan
A
501-1000 Employees
-
Key takeaway
Minaris Regenerative Medicine is a prominent CDMO specializing in the development and manufacturing of cell and gene therapy products, highlighting their expertise and state-of-the-art facilities that support global supply. Their commitment to quality and efficiency, particularly in QP Batch Certification, underscores their role as a reliable partner in the cell therapy landscape.
Reference
Service
QP Batch Certification | Minaris Regenerative Medicine
For cell and gene therapy products manufactured outside the European Union, Minaris Regenerative Medicine offers batch release to the EU market by Qualified Persons (QP).
T Cell Nouveau
Tokyo, Japan
A
1-10 Employees
2021
Key takeaway
T Cell Nouveau Inc. is advancing cancer treatment through its innovative Hybrid CAR T-cell therapy, which they believe represents a significant breakthrough in addressing solid tumors. Their expertise in pharmaceuticals and cancer immunotherapeutics underscores their commitment to pioneering research in this field.
Reference
Product
Technology | T Cell Nouveau Inc.
CAR-T細胞治療 自己由来CAR-T細胞治療
GenomeMiner (formerly Tupac.Bio)
Onna, Japan
A
1-10 Employees
2015
Key takeaway
The company specializes in bioinformatics and the sustainable production of natural products, highlighting its commitment to innovative solutions and the development of in-house assets.
Reference
Core business
home
Linical
Japan
A
501-1000 Employees
2005
Key takeaway
Linical emphasizes its commitment to streamlining the clinical development process, which may be beneficial for efficient cell line development. Their expertise in overcoming obstacles and expediting timelines could enhance the success of related projects.
Reference
Core business
Company Overview » Linical
Libra Medicina
Sapporo, Japan
A
1-10 Employees
2009
Key takeaway
LibraMedicina Ltd. specializes in the creation of new medicines and medical devices, offering development support services that include consulting for pharmaceutical development and preclinical research. They emphasize their strong connections with clinical research institutes, particularly in cancer, which may be relevant for those interested in cell line development.
Reference
Service
Consulting for pharmaceutical development, functional food development - リブラメディシーナ
Consulting for pharmaceutical development We provide support services for designing and implementing development plans related to preclinical and clinical research. Especially in the field of cancer, we have strong ties with leading clinical research institutes which have a wealth of knowledge and experience in clinical trials. Consulting for functional food development We have extensive experience in development planning, preclinical evaluation, and clinical trials for functional foods in various fields, and will support your development. For more information, please contact us.
Technologies which have been searched by others and may be interesting for you:
In the Cell Line Development industry in Japan, several key considerations play a crucial role for those interested in this sector. The regulatory landscape is a primary factor, as Japan has strict guidelines governing biotechnology and pharmaceutical research, which includes compliance with the Pharmaceuticals and Medical Devices Act. Understanding these regulations is essential for entering the market. Additionally, the industry faces challenges such as the high cost of development and the need for advanced technology to ensure quality and efficiency. Opportunities abound due to Japan's strong focus on innovation and research, supported by significant investments in biotechnology. This positions the country as a leader in cell line development, particularly for biopharmaceuticals. Environmental concerns are also increasingly relevant, as companies must adhere to sustainability practices and consider the environmental impact of their operations. The competitive landscape is characterized by both local and international firms, making it essential to analyze existing players and their market strategies. Given Japan's significance in the global market, understanding international collaborations and partnerships can provide insights into potential growth opportunities. Overall, those exploring this industry should prioritize regulatory knowledge, technological advancements, and market dynamics to navigate the complexities of cell line development in Japan effectively.
Some interesting numbers and facts about your company results for Cell Line Development
| Country with most fitting companies | Japan |
| Amount of fitting manufacturers | 23 |
| Amount of suitable service providers | 15 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 2002 |
| Youngest suiting company | 2021 |
Some interesting questions that has been asked about the results you have just received for Cell Line Development
What are related technologies to Cell Line Development?
Based on our calculations related technologies to Cell Line Development are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of Cell Line Development?
Start-Ups who are working in Cell Line Development are T Cell Nouveau
Which industries are mostly working on Cell Line Development?
The most represented industries which are working in Cell Line Development are Biotechnology, Other, IT, Software and Services, Chemicals, Consulting
How does ensun find these Cell Line Development Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.